


CLAIMS

1. A compound of Formula (I) or a pharmaceutically acceptable salt, solvate, chelate, or non-covalent complex thereof,



Formula (I)

--- is a single bond or a double bond;

L is C, Q is N, T is selected from the group consisting of O, CH₂ and CR₁₇;

ring A is C₆₋₁₀ aryl, substituted C₆₋₁₀ aryl, 5 to 10 membered heteroaryl, substituted 5 to 10 membered heteroaryl, 5 to 10 membered heterocyclyl, substituted 5 to 10 membered heterocyclyl; wherein the 5 to 10 membered heteroaryl or 5 to 10 membered heterocyclyl optionally containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

R₁ is selected from the group consisting of hydrogen, halogen, C₁₋₈ alkyl, substituted C₁₋₈ alkyl, C₁₋₈ alkoxy, substituted C₁₋₈ alkoxy, C₂₋₈ alkenyl, substituted C₂₋₈ alkenyl, C₂₋₈ alkynyl and substituted C₂₋₈ alkynyl;

R₂ is selected from the group consisting of C₃₋₁₀ cycloalkyl, substituted C₃₋₁₀ cycloalkyl, 3 to 10 membered heterocyclyl, substituted 3 to 10 membered heterocyclyl, C₆₋₁₀ aryl, substituted C₆₋₁₀ aryl, 6 to 10 membered heteroaryl and substituted 6 to 10 membered heteroaryl, wherein the 3 to 10 membered heterocyclyl or 6 to 10 membered heteroaryl optionally containing 1 or 2 heteroatoms selected from N and O ;

R₂ is optionally substituted with 1-2 R₁₃ substituents;

R₁₃ is selected from the group consisting of hydroxyl, halogen, C₁₋₈ alkyl, substituted C₁₋₈ alkyl, C₂₋₈ alkenyl, substituted C₂₋₈ alkenyl, C₂₋₈ alkynyl, substituted C₂₋₈ alkynyl, C₁₋₈ alkoxy, substituted C₁₋₈ alkoxy, C₆₋₁₀ aryl, substituted C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, substituted C₃₋₁₀ cycloalkyl, 3 to 10 membered heterocyclyl, substituted 3 to 10 membered heterocyclyl, 5 to 10 membered heteroaryl, substituted 5 to 10 membered heteroaryl, -NR₁₄R₁₅ and -CO-R₁₆, wherein

the 3 to 10 membered heterocyclyl or 5 to 10 membered heteroaryl optionally containing 1, 2 or 3 heteroatoms selected from N and O;

R₁₃ is optionally substituted with 0-1 R₁₈ substituent;

R₁₈ is selected from the group consisting of hydroxyl, halogen, C₁₋₈ alkyl, substituted C₁₋₈ alkyl, C₂₋₈ alkenyl, substituted C₂₋₈ alkenyl, C₂₋₈ alkynyl, substituted C₂₋₈ alkynyl, C₁₋₈ alkoxy, substituted C₁₋₈ alkoxy, C₆₋₁₀ aryl, substituted C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, substituted C₃₋₁₀ cycloalkyl, 3 to 10 membered heterocyclyl, substituted 3 to 10 membered heterocyclyl, 5 to 10 membered heteroaryl and substituted 5 to 10 membered heteroaryl, wherein the 3 to 10 membered heterocyclyl or 5 to 10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N and O;

R₅, R₆, R₇ and R₈ is independently selected from the group consisting of hydroxyl, halogen, C₁₋₈ alkoxy, substituted C₁₋₈ alkoxy, C₁₋₈ alkyl, substituted C₁₋₈ alkyl, C₂₋₈ alkenyl, substituted C₂₋₈ alkenyl, C₂₋₈ alkynyl, substituted C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, substituted C₃₋₈ cycloalkyl, C₆₋₁₀ aryl, substituted C₆₋₁₀ aryl, 5 to 10 membered heteroaryl, substituted 5 to 10 membered heteroaryl, 3 to 10 membered heterocyclyl and substituted 3 to 10 membered heterocyclyl;

R₉ is selected from the group consisting of H, halogen, amino, cyano, C₁₋₈ alkyl, substituted C₁₋₈ alkyl, C₁₋₈ alkoxy, substituted C₁₋₈ alkoxy, C₂₋₈ alkenyl, substituted C₂₋₈ alkenyl, C₂₋₈ alkynyl, substituted C₂₋₈ alkynyl, C₆₋₁₀ aryl, substituted C₆₋₁₀ aryl, C₃₋₈ cycloalkyl, substituted C₃₋₈ cycloalkyl, 3 to 10 membered heterocyclyl, substituted 3 to 10 membered heterocyclyl, 5 to 10 membered heteroaryl and substituted 5 to 10 membered heteroaryl;

R₉ is optionally substituted with 0-1 R₁₀ substituent;

R₁₀ is selected from the group consisting of hydroxyl, halogen, C₁₋₈ alkyl, substituted C₁₋₈ alkyl, C₂₋₈ alkenyl, substituted C₂₋₈ alkenyl, C₂₋₈ alkynyl, substituted C₂₋₈ alkynyl, C₁₋₈ alkoxy, substituted C₁₋₈ alkoxy, C₆₋₁₀ aryl, substituted C₆₋₁₀ aryl, C₃₋₈ cycloalkyl, substituted C₃₋₈ cycloalkyl, 3 to 10 membered heterocyclyl, substituted 3 to 10 membered heterocyclyl, 5 to 10 membered heteroaryl, substituted 5 to 10 membered heteroaryl, -CO-R₁₆ and -(CH₂)_nNR₁₁R₁₂;

R₁₁ or R₁₂ is optionally selected from the group consisting of H, C₁₋₈ alkyl, substituted C₁₋₈ alkyl, C₂₋₈ alkenyl, substituted C₂₋₈ alkenyl, C₂₋₈ alkynyl, substituted C₂₋₈ alkynyl, C₁₋₈ alkoxy, substituted C₁₋₈ alkoxy, C₃₋₈ cycloalkyl, substituted C₃₋₈ cycloalkyl, C₆₋₁₀ aryl, substituted C₆₋₁₀ aryl,

5 to 10 membered heteroaryl, substituted 5 to 10 membered heteroaryl, 3 to 10 membered heterocyclyl and substituted 3 to 10 membered heterocyclyl;

R_{14} or R_{15} is optionally selected from the group consisting of H, C_{1-8} alkyl, substituted C_{1-8} alkyl, C_{2-8} alkenyl, substituted C_{2-8} alkenyl, $-CO-C_{2-8}$ alkenyl, substituted $-CO-C_{2-8}$ alkenyl, C_{2-8} alkynyl, substituted C_{2-8} alkynyl, C_{3-10} cycloalkyl, substituted C_{3-10} cycloalkyl, C_{6-10} aryl, substituted C_{6-10} aryl, 5 to 10 membered heteroaryl, substituted 5 to 10 membered heteroaryl, 3 to 10 membered heterocyclyl and substituted 3 to 10 membered heterocyclyl;

R_{16} is optionally selected from the group consisting of C_{1-8} alkyl, substituted C_{1-8} alkyl, C_{2-8} alkenyl, substituted C_{2-8} alkenyl, C_{2-8} alkynyl, substituted C_{2-8} alkynyl, C_{3-10} cycloalkyl, substituted C_{3-10} cycloalkyl, C_{6-10} aryl, substituted C_{6-10} aryl, 5 to 10 membered heteroaryl, substituted 5 to 10 membered heteroaryl, 3 to 10 membered heterocyclyl, substituted 3 to 10 membered heterocyclyl and $-NR_{11}R_{12}$;

R_{17} is selected from the group consisting of C_{1-8} alkyl, substituted C_{1-8} alkyl, C_{2-8} alkenyl, substituted C_{2-8} alkenyl, C_{2-8} alkynyl, substituted C_{2-8} alkynyl, C_{3-10} cycloalkyl, substituted C_{3-10} cycloalkyl, C_{6-10} aryl, substituted C_{6-10} aryl, 5 to 10 membered heteroaryl, substituted 5 to 10 membered heteroaryl, 3 to 10 membered heterocyclyl, substituted 3 to 10 membered heterocyclyl, or R_{17} is C_{3-10} cycloalkyl, taken together with the carbon atom to which they are attached form a spiro ring;


M is 0 or 1;

N is 0, 1 or 2;

and provided that:

if ring A is a 5-member heteroaryl containing 2 or 3 N atoms, then R_2 is vinylamide substituted 6-member heterocyclyl comprising oxygen heteroatom, wherein vinylamide substituted 6-member heterocyclyl optionally substituted with 0-1 R_{13} substituent.

2. The compound of claim 1, wherein the compound is shown as formula (II):




Formula (II).

3. The compound of claim 1 or 2, wherein ring A is phenyl, 5 to 6 membered heteroaryl or 10 membered heterocyclyl, wherein the 5 to 6 membered heteroaryl optionally containing 1, 2 or 3 heteroatoms selected from N and S, the 10 membered heterocyclyl is a fused bicyclic which has two N atoms and one O atom in the ring.

5 4. The compound of any one of claims 1-3, wherein ring A is 6 membered heteroaryl.

5. The compound of any one of claims 1-3, wherein R₉ is selected from the group consisting of H, halogen, cyano, C₁₋₆ alkyl, halogen substituted C₁₋₆ alkyl, -(CH₂)_nNR₁₁R₁₂ substituted amino, C₁₋₆ alkoxy which substituted with substituted 6 membered heterocyclyl, wherein R₁₁ and R₁₂ are each optionally selected from C₁₋₆ alkyl.


10 6. The compound of any one of claims 1-3, wherein



7. The compound of any one of claims 1-3, wherein R₁ is hydrogen, R₂ is selected from the group consisting of C₅₋₆ cycloalkyl, substituted C₅₋₆ cycloalkyl, 5 to 7 membered heterocyclyl, substituted 5 to 7 membered heterocyclyl and phenyl, wherein the 5 to 7 membered heterocyclyl optionally containing 1 or 2 heteroatoms selected from N and O.

8. The compound of any one of claims 1-3, wherein R₂ is substituted with 1 or 2 R₁₃ substituents, R₁₃ is selected from the group consisting of 5 to 6 membered heterocyclyl, substituted 5 to 6 membered heterocyclyl, -NR₁₄R₁₅ and -CO-R₁₆, R₁₄ is H, R₁₅ is -CO-C₂₋₄ alkenyl, R₁₆ is C₁₋₃ alkyl or substituted C₁₋₃ alkyl.

9. The compound of any one of claims 1-3, wherein R₁₃ is substituted with 0-1 R₁₈ substituent, R₁₈ is selected from the group consisting of C₁₋₆ alkyl, 5 to 6 membered heterocyclyl and substituted 5 to 6 membered heterocyclyl, wherein the 5 to 6 membered heterocyclyl containing 1 or 2 heteroatoms selected from N and O.



11. The compound of any one of claims 1-3, wherein R₅, R₆, R₇ and R₈ are each independently selected from the group consisting of hydrogen, halogen, C₁₋₃ alkoxy and substituted C₁₋₃ alkoxy.

5 12. The compound of any one of claims 1-11, wherein R₅ and R₈ are selected from the following groups:

- (i) both R₅ and R₈ are chlorine;
- (ii) both R₅ and R₈ are hydrogen;
- (iii) R₅ is hydrogen, R₈ is chlorine; or
- 10 (iv) R₅ is chlorine, R₈ is hydrogen.

13. The compound of any one of claims 1-12, wherein R₆ and R₇ are selected from the following groups:

- (i) both R₆ and R₇ are methoxy;
- (ii) R₆ is methoxy, R₇ is H; or
- 15 (iii) R₆ is H, R₇ is methoxy.

14. The compound of any one of claims 1-13, wherein m is 0 or 1.

15. The compound of any one of claims 1-14, wherein n is 2.

16. A compound or a pharmaceutically acceptable salt, wherein the compound is selected from:

- 20 (1) *N*-(2-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)-5-(4-morpholinopiperidin-1-yl)phenyl)acrylamide;
- (2) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;

- (3) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5-oxo-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (4) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5-methyl-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- 5 (5) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrimido[5,4-*e*][1,2,4]triazolo[4,3-*a*]pyrimidin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (6) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrimido[5,4-*c*]quinolin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (7) *N*-((3*R*,4*S*)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide;
- 10 (8) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrimido[5,4-*c*][1,5]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (9) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrido[2,3-*d*:4,5-*d'*]dipyrimidin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- 15 (10) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrazino[2',3':5,6]pyrido[4,3-*d*]pyrimidin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (11) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-9-fluoro-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (12) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-10-methyl-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- 20 (13) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-9-methyl-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (14) *N*-((3*S*,4*S*)-3-((6-(2-chloro-3,5-dimethoxyphenyl)-9-methyl-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- 25 (15) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-methyl-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;

- (16) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-9-(trifluoromethyl)-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (17) *N*-((3*S*,4*S*)-3-((6'-(2,6-dichloro-3,5-dimethoxyphenyl)-6'*H*-spiro[cyclopropane-1,5'-pyrimido[5,4-*c*][1,8]naphthyridin]-2'-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- 5 (18) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)pyrimido[4,5-*f*][1,7]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (19) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5-methyl-5,6-dihydrothieno[3',4':5,6]pyrido[4,3-*d*]pyrimidin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (20) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-6*H*-pyrido[3',2':4,5]pyrano[3,2-*d*]pyrimidin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- 10 (21) *N*-((3*S*,4*S*)-3-((6-(2-chloro-5-methoxyphenyl)-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (22) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-6,9,10,11-tetrahydro-5*H*-[1,4]oxazino[2,3-*b*]pyrimido[4,5-*f*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- 15 (23) *N*-((3*R*,4*S*)-4-((10-(2-(4-acryloylpiperazin-1-yl)ethoxy)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide;
- (24) *N*-((3*R*,4*S*)-1-acetyl-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)piperidin-4-yl)acrylamide;
- 20 (25) *N*-((3*S*,4*S*)-3-((4-(2,6-dichloro-3,5-dimethoxyphenyl)-5-methyl-4,5-dihydrothiazolo[5',4':5,6]pyrido[4,3-*d*]pyrimidin-8-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- (26) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-9-((2-(dimethylamino)ethyl)amino)-5,6-dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;
- 25 (27) *N*-((3*S*,4*R*)-4-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrimido

[5,4-*c*][1,8]naphthyridin-2-yl)amino)-1-(1-methylpiperidin-4-yl)pyrrolidin-3-yl)acrylamide;

(28) *N*-((3*S*,4*S*)-3-((9-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-

dihydropyrimido[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;

(29) *N*-((3*S*,4*S*)-3-((9-cyano-6-(2,6-dichloro-3,5-dimethoxyphenyl)-5,6-dihydropyrimido

5 [5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;

(30) *N*-((3*S*,4*S*)-3-((6-(2-chloro-5-methoxyphenyl)-9-methyl-5,6-dihydropyrimido

[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;

(31) *N*-((3*S*,4*S*)-3-((6-(2-chloro-3-methoxyphenyl)-9-methyl-5,6-dihydropyrimido

[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;

10 (32) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3-methoxyphenyl)-9-methyl-5,6-dihydropyrimido

[5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide;

(33) *N*-((3*S*,4*S*)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-[1,2,4]triazolo

[4',3':1,6]pyrido[2,3-*d*]pyrimidin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide; or

(34) *N*-(3-((9-chloro-6-(2,6-dichloro-3,5-dimethoxyphenyl)-5-oxo-5,6-dihydropyrimido

15 [5,4-*c*][1,8]naphthyridin-2-yl)amino)tetrahydro-2*H*-pyran-4-yl)acrylamide.

17. A pharmaceutical composition comprising a therapeutically effect amount of compound according to any one of claims 1-16 and at least one pharmaceutically acceptable excipient.

18. A pharmaceutical composition of claim 17, wherein a mass ratio of the said compound and the pharmaceutically acceptable excipient is 0.0001:1-10.

20 19. The pharmaceutical composition of claim 17 or 18, wherein the pharmaceutical composition is used in treating or preventing disease mediated FGFR4.

20. The pharmaceutical composition of claim 19, wherein the disease mediated FGFR4 is cancer.

25 21. The pharmaceutical composition of claim 20, wherein the cancer is selected from the group consisting of breast cancer, multiple myeloma, bladder cancer, endometrial cancer, gastric cancer, cervical cancer, rhabdomyosarcoma, non-small cell lung cancer, small cell lung cancer, pleomorphic lung cancer, ovarian cancer, esophageal cancer, melanoma, colorectal cancer , Hepatocellular carcinoma, head and neck tumors, hepatobiliary cell carcinoma, myelodysplastic syndrome, malignant glioma, prostate cancer, thyroid cancer, Schwann cell tumor, lung

squamous cell carcinoma, lichenoid keratosis, Synovial sarcoma, skin cancer, pancreatic cancer, testicular cancer or liposarcoma.

22. The pharmaceutical composition of any one of claims 19-21, wherein the subject is human.

23. Use of the compound according to any one of claims 1-16 or the pharmaceutical
5 composition according to claim 17 or 18 in the manufacture of a medicament.

24. The use of claim 23, wherein the medicament is used in the treatment, prevention or delay of the occurrence or progression of cancer or cancer metastasis.

25. Use of the compound according to any one of claims 1-16 or the pharmaceutical composition according to claim 17 or 18 in the manufacture of a medicament for use in the
10 treatment of disease mediated by FGFR4.

26. The use of claim 25, wherein the disease is cancer.

27. The use of claim 24 or 26, wherein the cancer is selected from the group consisting of breast cancer, multiple myeloma, bladder cancer, endometrial cancer, gastric cancer, cervical cancer, rhabdomyosarcoma, non-small cell lung cancer, small cell lung cancer, pleomorphic lung
15 cancer, ovarian cancer, esophageal cancer, melanoma, colorectal cancer , Hepatocellular carcinoma, head and neck tumors, hepatobiliary cell carcinoma, myelodysplastic syndrome, malignant glioma, prostate cancer, thyroid cancer, Schwann cell tumor, lung squamous cell carcinoma, lichenoid keratosis, Synovial sarcoma, skin cancer, pancreatic cancer, testicular cancer or liposarcoma.

20 28. The use of claim 23, wherein the medicament is used as FGFR4 inhibitor.